Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary preclinical studies for M102 to initiate its first-in-human studies. The agency has also provided valuable guidance to support the clinical development of M102.
Aclipse Therapeutics receives a therapeutic development award of $1.475 million
Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the